Over the last 7 days, the United States market has seen a decline of 4.1%, yet it remains up by 21% over the past year with earnings projected to grow by 18% annually in the coming years. In this cont
Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 13, H.C. Wainwright reiterated Intellia Therapeutics (NASDAQ:NTLA) as a Buy but low
Intellia Therapeutics Inc. (NASDAQ:NTLA) is one of the 9 Stocks Crushing the Market With Surging Returns. Intellia Therapeutics snapped a three-day losing streak on Thursday, soaring 13.29 percent to
The United States market has recently seen a 1.2% increase over the past week and an impressive 27% rise over the last year, with earnings expected to grow by 17% annually. In this thriving environmen
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.
The United States market has experienced a notable upswing, climbing 2.5% in the last week and an impressive 26% over the past year, with earnings expected to grow by 17% annually. In this dynamic env
View interactive chart, options flow, and AI analysis for NTLA on Zorveq Finance.
Open NTLA Chart & Analysis →